Recursion Pharmaceuticals, Inc. (RXRX) · Aug 5, 2026 · Company update

Revenue missed consensus as spending guidance fell; Genentech advanced a target.

Revenue missed consensus as spending guidance fell; Genentech advanced a target.

The quarter fell short on the two headline financial measures the market was watching. Total revenue of $7.7 million was about 37% below the published consensus of roughly $12.2 million, while the $0.25 per-share loss was slightly wider than the roughly $0.23 expected loss. The revenue decline was attributed to fewer Roche/Genentech project phases completing than in the prior-year quarter—not a stated loss of a partner—yet it reinforces how variable collaboration revenue remains. (Condensed Statements of Operations; Revenue discussion)

MetricQ2 2026 actualComparisonRead versus expectation
Total revenue$7.7M$19.2M in Q2 2025; published consensus ~$12.2MBelow consensus
Net loss per share$(0.25)$(0.41) in Q2 2025; published consensus ~$(0.23)Slightly worse than expected
Net loss$(131.0)M$(171.9)M in Q2 2025Improved year over year
R&D expense$89.6M$128.6M in Q2 2025Lower, partly aided by lower non-cash Tempus data expense
H1 cash operating expense$191.0M$199.1M in H1 2025Lower year over year
Full-year cash operating expense guidance$375MReduced by $15M from prior guidanceConstructive offset
Cash and equivalents$545.7M$743.3M at December 31, 2025Material cash drawdown remains

The cost reset is the clearest offset, but it does not erase the revenue miss. Management cut full-year cash operating expense guidance by $15 million to $375 million, after H1 cash operating expense declined to $191 million from $199.1 million. That supports the efficiency story and helped narrow the accounting loss year over year. But quarterly operating cash use rose to $105.9 million from $76.4 million, even if the prior year benefited from a $28.6 million UK R&D tax-credit inflow; cash and equivalents still declined by about $198 million since year-end. (Cash Operating Expense reconciliation; Condensed Statements of Cash Flows; Condensed Balance Sheets)

The Genentech milestone is strategically credible but still early-stage rather than near-term revenue. Genentech exercised its first validated-target option in the neuroscience collaboration, moving a previously unexplored target into joint small-molecule discovery. That is a useful external validation of the platform—the partner is advancing an internally generated target—but the filing does not disclose a new payment tied to this option, and the program remains before clinical development. It improves the platform proof-point more than it changes near-term financial expectations. (Genentech neuroscience collaboration update)

Pipeline execution met the stated timetable without providing a new clinical-value inflection. REC-7735 cleared its IND and is set to enter Phase 1/2 in the second half of 2026, while additional REC-4881 Phase 2 data are scheduled for November. These are tangible advances, but they were schedule confirmations and future data commitments rather than new efficacy results in this filing. (Pipeline updates — REC-7735; Continued Momentum for REC-4881)

Net: the filing is weaker than expected financially, with lower spending guidance and partner validation limiting—but not reversing—the shortfall.

Original filing on SEC EDGAR

More Recursion Pharmaceuticals, Inc. news

Revenue missed consensus as spending guidance fell; Genentech advanced a target. | RXRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.